news
NICE recommends new Fabry disease treatment
Recommendation of Elfabrio® (pegunigalsidase alfa) means patients with Fabry disease in England will be able to access a new treatment option.
List view / Grid view
National Institute for Health and Clinical Excellence (NICE)
news
NICE recommends therapy duo for advanced leukaemia
Janssen states Imbruvica® plus venetoclax will provide "a much-needed new treatment option" for chronic lymphocytic leukaemia.
news
NICE recommends Daklinza for chronic HCV
16 October 2015 | By Victoria White
NICE has recommended Daklinza for the treatment of patients with chronic hepatitis C virus genotypes 1, 3 and 4...
news
Another NICE recommendation for melanoma drug Keytruda
9 October 2015 | By Victoria White
This new recommendation for Keytruda is for treating advanced melanoma that has not been previously treated with ipilimumab...
news
NICE says ‘yes’ to pembrolizumab for advanced melanoma
7 October 2015 | By
Pembrolizumab was the first drug to be approved through the Medicines and Healthcare Products Regulatory Agency’s Early Access to Medicine Scheme (EAMS)...
news
NICE recommends idelalisib for chronic lymphocytic leukaemia
24 September 2015 | By Victoria White
Idelalisib has been recommended in combination with rituximab for adults with chronic lymphocytic leukaemia (CLL) who have relapsed early...
news
NICE recommends blood-thinning drug edoxaban
23 September 2015 | By Victoria White
NICE has issued its final recommendation for edoxaban to help prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation...
news
NICE recommends melanoma drug pembrolizumab
7 September 2015 | By Victoria White
NICE has recommended that pembrolizumab is made available on the NHS as a treatment for some patients with advanced melanoma which is either unresectable or metastatic...
news
NICE recommends RoActemra for severe rheumatoid arthritis
4 September 2015 | By Victoria White
RoActemra has been recommended by NICE for the treatment of patients with severe rheumatoid arthritis whose disease has not responded to intensive therapy with a combination of cDMARDs...
news
NICE says ‘no’ to apremilast for psoriatic arthritis
3 September 2015 | By Victoria White
NICE has published final draft guidance which does not recommend apremilast, saying that there is not enough evidence to demonstrate apremilast slows progression of psoriatic arthritis...
news
NICE draft guidance conditionally recommends Vimizim
2 September 2015 | By Victoria White
NICE has provisionally recommended BioMarin’s Vimizim for the treatment of the very rare inherited lysosomal storage disease, mucopolysaccharidosis type IVa...
news
NICE recommends vedolizumab for Crohn’s Disease
26 August 2015 | By Victoria White
NICE has recommended Vedolizumab, the first gut-selective treatment for Crohn's Disease, for use on the NHS, recognising the innovation of the treatment...
news
NICE recommends edoxaban for deep vein thrombosis
26 August 2015 | By Victoria White
NICE has recommended once-daily edoxaban for the treatment and prevention of recurrent DVT and pulmonary embolism, saying the drug is cost-effective for the NHS...
news
NICE tackles overuse of antibiotics
18 August 2015 | By Victoria White
NICE, the UK health watchdog, has published guidance to help doctors, nurses and pharmacists promote and monitor the sensible use of antibiotics...
news
NICE asks for more information on ovarian cancer drug olaparib
6 August 2015 | By Victoria White
NICE has opened a second consultation on preliminary draft guidance on olaparib for maintenance treatment of ovarian, fallopian tube and peritoneal cancer...
